Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients.
Madelaine BeckettJulia TanEvelyne BonnardeauxJan P DutzKamran ShojaniaFergus ToAnthony ObrzutJ Aviña-ZubietaKun HuangPublished in: Rheumatology (Oxford, England) (2023)
Tofacitinib appears to be highly effective in targeting cutaneous manifestations in classic DM and ADM; however, minimal benefit in muscle strength in the DM or PM phenotype were observed.
Keyphrases
- rheumatoid arthritis
- ulcerative colitis
- interstitial lung disease
- particulate matter
- air pollution
- glycemic control
- oxidative stress
- heavy metals
- cancer therapy
- polycyclic aromatic hydrocarbons
- type diabetes
- stem cells
- systemic sclerosis
- water soluble
- risk assessment
- adipose tissue
- metabolic syndrome
- mesenchymal stem cells
- cell therapy
- insulin resistance
- bone marrow